Feb 7th (Fri) 9PM NY

Deal Alert: High-Growth Commercial Concrete Sealing Business

📍 Location: Undisclosed (Commercial & Industrial Focus)
💰 Asking Price: $2.1M (Just over 3x cash flow)
📊 Revenue: $2.15M forecasted for 2024
💼 Cash Flow: $646K projected for 2024

🌟 Why This Business is Great:

Incredible Growth with Minimal Effort:

• Revenue has nearly tripled in just three years, climbing from $656K in 2021 to a projected $2.15M in 2024.

• Cash flow has seen a 220% increase in the same period—all without a marketing strategy or a full sales team.

Repeat Business & Loyal Customers:

• 80% of revenue comes from repeat customers, signaling strong client relationships and consistent demand.

• The business thrives on its reputation, without relying on advertising or aggressive outreach.

Lean Operations, Big Potential:

• A single salesperson handles all estimates, leaving room to double the pipeline with the addition of just one more estimator.

• No online presence or digital marketing means there’s a huge untapped growth opportunity.

🚀 Growth Opportunities:

• Expand the Sales Team: Adding another estimator can immediately increase project volume and open new contractor relationships.

• Launch Basic Marketing: Simple tactics like SEO, social media presence, and cold outreach could unlock new revenue streams.

• Scale with Existing Backlog: With a strong backlog of projects, scaling operations will directly boost revenue without needing to source additional work immediately.

🔍 My Analysis: This business is a solid opportunity for anyone looking to step into a high-growth, low-risk venture. It’s been growing fast without any real marketing or a full sales team, which means there’s huge potential to scale with just a few simple changes. Adding another estimator and doing basic marketing like social media or SEO could easily double the revenue. The asking price is fair at just over 3x cash flow, especially given the strong repeat customer base and consistent growth. The biggest thing to watch is making sure the transition with existing clients is smooth since the business relies on strong relationships. Overall, it’s a great deal for the right buyer ready to take it to the next level.

🏃‍♂️Want to buy this business? If you want access to this deal and others like it, book a call with us. We'll show you how we can help you buy this business or others like it, show you how to analyze and help you finance this deal or others like it, and discuss our paid program where we can help you find, finance, and acquire a business or few of them in the next 6-12 months.

Join A Free Training To Apply To Become an Acquisitions.com Advisor: Learn how to broker the buying and selling of businesses, and earn monthly retainers, and 2-10% of each deal.

Together with MoneyPickle

Optimize Your Financial Future

Working with a financial advisor used to feel like a significant commitment, but Money Pickle makes it easy—and completely free—to explore the benefits without the hassle. 

Our quick matching quiz connects you with a vetted advisor who understands your unique situation. You can schedule a convenient video chat at a time that works for you, where you’ll dive into important topics like tax efficiency, estate planning, and Social Security.

It’s a chance to see how personalized advice could work for you—no obligation required. If you find value in the conversation, you can take the next steps; if not, you leave with valuable insights. 

Money Pickle simplifies the process, helping you make an informed choice with confidence.

Recent Case Study

From a dentist to a $4M business owner [link]

Recent Acquisition Stories:
Relmada Therapeutics Acquires Potential Tourette Syndrome Treatment

Relmada Therapeutics (Nasdaq: RLMD), a clinical-stage biotech company, has acquired Sepranolone from Asarina Pharma AB. Sepranolone, a Phase 2b-ready neurosteroid, shows promise in treating Tourette syndrome (TS) and other compulsive disorders. Early clinical data reveals significant reductions in tics and improvements in quality of life, all without serious side effects—a big deal in the CNS drug space. Relmada sees this as a strategic fit to bolster its pipeline for hard-to-treat neurological conditions.

My Take:
This acquisition is a smart move for Relmada, targeting a niche with limited effective treatments. The strong Phase 2a data and Sepranolone's clean safety profile could position it as a first-line therapy if later trials hold up. However, with Relmada's stock price sitting at $0.34 and analysts rating it a "Sell," they’ll need more than promising data to regain investor confidence. This deal reflects a growing trend of smaller biotech firms leveraging acquisitions to build value, but execution will be key.

Scale or Sell

If you're a business owner looking to scale your company to 8 or 9 figures, we can help. Our 70+ pillars alongside our “Scale or Sell” system provides a clear roadmap to improve your operations and profitability and look to get personalized guidance, access our proprietary growth tools, and learn how to build a valuable, sellable enterprise reply back with details about your business and the type of help you look for.

Recent Youtube Video

How To Finally Buy A Business [link]

Here’s How We Can Help You:

• Join Our Community: Access free courses & meet fellow entrepreneurs. (link)

• Buy a Business: Get support with finding, analyzing & financing deals (link)

• Become an Acquisitions.com Advisor: Help others buy and sell businesses. (link)

• Scale your business: Build Internal foundations before external growth (link)

• Sell a Business: Connect with interested buyers. (link)

• Co-invest with Us: Partner on lucrative deals. (link)